Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
ViroMissile, Inc.
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
MacroGenics
City of Hope Medical Center
M.D. Anderson Cancer Center
NeoTX Therapeutics Ltd.
AccSalus Biosciences, Inc.
West China Hospital
HiFiBiO Therapeutics
Chiome Bioscience Inc.
Pfizer
University of Virginia
Incyte Corporation
Incyte Corporation
Sotio Biotech Inc.
Molecular Templates, Inc.
National Cancer Institute (NCI)
Xencor, Inc.
Pliant Therapeutics, Inc.
BioEclipse Therapeutics
Atreca, Inc.
University of Florida
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Provectus Pharmaceuticals
AbbVie
Pfizer
AbbVie
Incyte Corporation
Incyte Corporation
Polaris Group
Abramson Cancer Center at Penn Medicine
Sichuan Huiyang Life Science and Technology Corporation
AbbVie
Mirna Therapeutics, Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
Angiochem Inc
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center